Lead Product(s): GYROX-1
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: University of Tokyo Edge Capital
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2020
This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development.